Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × INDUSTRY × Malignant Disease × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1517 Carcinoma, Non-Small-Cell Lung 749 Breast Neoplasms 567 Neoplasm Metastasis 526 Colorectal Neoplasms 437 Melanoma 389 Leukemia, Myeloid, Acute 368 Multiple Myeloma 359 Ovarian Neoplasms 349 Recurrence 333 Lymphoma 333 Advanced Solid Tumors 318 Lymphoma, Non-Hodgkin 313 Prostatic Neoplasms 294 Pancreatic Neoplasms 286 Advanced Solid Tumor 240 Stomach Neoplasms 230 Carcinoma, Renal Cell 224 Squamous Cell Carcinoma of Head and Neck 210 Lung Neoplasms 208 Solid Tumor 202 Leukemia, Lymphocytic, Chronic, B-Cell 198 Triple Negative Breast Neoplasms 182 Solid Tumors 181 Carcinoma, Hepatocellular 162 Hematologic Neoplasms 153 Head and Neck Neoplasms 151 Lymphoma, Large B-Cell, Diffuse 147 Glioblastoma 144 Lymphoma, Follicular 143

Interventions

amuvatinib 1 Topotecan 1 Paclitaxel 1 Etoposide 1 Erlotinib Hydrochloride 1 Docetaxel 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00881166 2024-08-02

SGI-0470-02

Astex Pharmaceuticals, Inc.

Phase 1 Completed

Malignant Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡